|
Reference
|
  |
Aliti, G.B., Rabelo, E.R., Clausell, N., i dr. (2013) Aggressive fluid and sodium restriction in acute decompensated heart failure a randomized clinical trial. JAMA Intern Med, 173: 1058-64 |
1 |
Al-Mohammad, A., Mant, J. (2011) The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. Heart, 97: 411-16 |
|
Banner, N.R., Bonser, R.S., Clark, A.L., i dr. (2011) UK guidelines for referral and assessment of adults for heart transplantation. Heart, 97: 1520-7 |
|
Böhm, M., Borer, J., Ford, I., i dr. (2013) Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol, 102: 11-22 |
|
Castagno, D., Petrie, M.C., Claggett, B., i dr. (2012) Should we SHIFT our thinking about digoxin?, Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J, 33: 1137-41 |
|
Chemaly, E.R., Hajjar, R.J., Lipskaia, L. (2013) Molecular targets of current and prospective heart failure therapies. Heart, 99: 992-1003 |
 |
Cleland, J.G., Clark, A.L. (2012) Heart failure-does it matter whether LVEF is reduced?. Lancet, 380(9851): 1363-1365 |
2  |
Costanzo, M.R., Guglin, M.E., Saltzberg, M.T., Jessup, M.L., Bart, B.A., Teerlink, J.R., Jaski, B.E., Fang, J.C., Feller, E.D., Haas, G.J., Anderson, A.S., Schollmeyer, M.P., Sobotka, P.A. (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. Journal of the American College of Cardiology, 49(6): 675-83 |
|
Deyell, M.W., Qi, A., Chakrabarti, S., i dr. (2013) Prognostic impact of inappropriate defibrillator shocks in a population cohort. Heart, 99: 1250-5 |
|
Edelmann, F., Wachter, R., Schmidt, A.G., i dr. (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA, 309: 781-91 |
|
Fröhlich, G.M., Holzmeister, J., Hübler, M., i dr. (2013) Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart, 99: 1158-65 |
|
Gheorghiade, M., Albaghdadi, M., Zannad, F., i dr. (2011) Rationale and design of the multicentre, randomized, double-blind, placebocontrolled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail, 13: 100-6 |
|
Gheorghiade, M., Böhm, M., Greene, S.J., i dr. (2013) Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA, 309: 1125-35 |
|
Goldacre, B. (2013) Are clinical trial data shared sufficiently today? No. BMJ, 347(jul09 1): f1880-f1880 |
|
Hardman, S.M. (2013) Ivabradine in heart failure: NICE guidance. Heart, 18 June 2013, http://heart.bmj.com/content/early/2013/06/17/heartjnl-2012-303490.fullpdf+html?sid=29e1ec6a-5827-4d48-95ac-87be0a60b7c6 |
|
Hauptman, P.J., Schwartz, P.J., Gold, M.R., i dr. (2012) Rationale and study design of the increase of vagal tone in heart failure study: INOVATE- HF. Am Heart J, 163: 954-62 |
|
Hawkins, N.M., Petrie, M.C., Burgess, M.I., i dr. (2009) Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony. J Am Coll Cardiol, 53: 1944-59 |
|
Heidenreich, P.A., Albert, N.M., Allen, L.A., i dr. (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail, 6: 606-19 |
|
Holland, R., Battersby, J., Harvey, I., i dr. (2005) Systematic review of multidisciplinary interventions in heart failure. Heart, 91: 899-906 |
|
Krum, H., Massie, B., Abraham, W.T., i dr. (2011) Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (. Eur J Heart Fail, 13: 107-14 |
|
Makkar, R.R., Smith, R.R., Cheng, K., i dr. (2012) Intracoronary cardiospherederived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet, 379: 895-904 |
|
Mcmurray, J.J., Pitt, B., Latini, R., i dr. (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail, 1: 17-24 |
|
Mcmurray, J.J., Abraham, W.T., Dickstein, K., i dr. (2012) ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail, 14: 341-3 |
1 |
Mcmurray, J.J., Adamopoulos, S., Anker, S.D., i dr. (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the. Eur Heart J, 33: 1787-847 |
1 |
Moss, A.J., Schuger, C., Beck, C.A., i dr. (2012) Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med, 367: 2275-83 |
|
Mostofsky, E., Rice, M.S., Levitan, E.B., i dr. (2012) Habitual coffee consumption and risk of heart failure: a dose-response meta-analysis. Circ Heart Fail, 5: 401-5 |
|
Mullens, W., Verga, T., Grimm, R.A., i dr. (2009) Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol, 53: 600-7 |
|
National Institute for Health and Care Excellence (2010) Chronic heart failure. u: Clinical guideline 108, London |
|
National Institute for Health and Care Excellence (2011) Chronic heart failure quality standard: QS9. London |
|
Packer, M., Colucci, W., Fisher, L., i dr. (2013) Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail, 1: 103-11 |
|
Pandor, A., Gomersall, T., Stevens, J.W., i dr. (2013) Remote monitoring after recent hospital discharge in patients with heart failure: A systematic review and network metaanalysis. Heart, Published Online First: 16 May http://heart.bmj.com/content/early/2013/05/15 /heartjnl-2013-303811.full.pdf+html?sid=25776cbc-1e08-4e6f-abc1-638828de7d98 |
|
Parving, H.H., Brenner, B.M., Mcmurray, J.J., i dr. (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med, 367: 2204-13 |
|
Phelan, D., Thavendiranathan, P., Collier, P., i dr. (2012) Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials. Heart, 98: 1693-700 |
|
Poole, J.E., Johnson, G.W., Hellkamp, A.S., i dr. (2008) Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med, 359: 1009-17 |
|
Schwartz, P.J., de Ferrari, G.M., Sanzo, A., i dr. (2008) Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail, 10: 884-91 |
|
Schwartz, P.J. (2012) Vagal stimulation for the treatment of heart failure: a translational success story. Heart, 98(23): 1687-1689 |
|
Shah, A.S., Langrish, J.P., Nair, H., i dr. (2013) Global association of air pollution and heart failure: A systematic review and meta-analysis. Lancet, Published Online First: 9 July 2013. doi:10.1016/ S0140-6736(08)61345-8 |
|
Solomon, S.D., Zile, M., Pieske, B., i dr. (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, 380: 1387-95 |
|
Swedberg, K., Komajda, M., Böhm, M., i dr. (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study. Lancet, 376: 875-85 |
|
Takeda, A., Taylor, S.J., Taylor, R.S., i dr. (2012) Clinical service organisation for heart failure. Cochrane Database Syst Rev, 9, CD002752 |
|
Tang, A.S., Wells, G.A., Talajic, M., i dr. (2010) Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med, 363: 2385-95 |
|
Teerlink, J.R., Metra, M., Felker, G.M., i dr. (2009) Relaxin for the treatment of patients with acute heart failure (Pre RELAX AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose- finding phase IIb study. Lancet, 373: 1429-39 |
|
Teerlink, J.R., Cotter, G., Davison, B.A., i dr. (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet, 381: 29-39 |
|
Thomas, R., Huntley, A., Mann, M., i dr. (2013) Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials. Heart, 99: 233-9 |
|
University College-National Centre for Cardiovascular Prevention and Outcomes (2012) National heart failure audit: April 2011-March 2012. London, https:// http://www.ucl.ac.uk/nicor/audits/ heartfailure/additionalfiles/pdfs/annualreports/annual12. pdf |
|
Verbrugge, F.H., Dupont, M., Vercammen, J., i dr. (2013) Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response. Heart, 99: 314-19 |
|
Witte, K.K. (2013) Cardiac resynchronisation therapy for chronic heart failure: predicting and measuring 'response. Heart, 99: 293-4 |
1 |
Yancy, C.W., Jessup, M., Bozkurt, B., i dr. (2013) ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, Published Online First: 5 June. http://circ.ahajournals.org/content/ early/2013/06/03/CIR.0b013e31829e8776.long |
| |
|
|